Iron Dextran

The dosage of Iron Dextran is highly individualized and must be calculated based on the patient's weight and current hemoglobin level. Healthcare providers typically use the Ganzoni formula or a standardized calculation to determine the total iron deficit.

• Total Iron Deficit (mg) = 0.3 x weight (lbs) x [100 - (Hb x 100 / 14.8)] + 1000 mg (for iron stores).
• For adults weighing over 30 lbs, the standard dose for a single IM injection should not exceed 100 mg (2 mL) per day.
• For IV administration, the total calculated dose may sometimes be given as a single large infusion (Total Dose Infusion or TDI), though this is often performed off-label and requires intense monitoring.

Iron Dextran may be used in pediatric patients with iron deficiency anemia. It is generally not recommended for infants under 4 months of age.

• Infants (5-10 kg): The maximum daily dose is typically 25 mg (0.5 mL).
• Children (10-20 kg): The maximum daily dose is typically 50 mg (1.0 mL).
• Children (over 20 kg): The maximum daily dose is typically 100 mg (2.0 mL).

As with adults, the total dose must be calculated based on the child's weight and hemoglobin deficit.

Renal Impairment

No specific dose adjustments are required for patients with renal impairment. However, iron status should be monitored closely in patients with chronic kidney disease (CKD), as they often require concurrent erythropoiesis-stimulating agents (ESAs).

Hepatic Impairment

Caution is advised in patients with severe liver disease. Since the liver is a primary site for iron storage and processing, iron overload must be avoided. Iron Dextran should be avoided in patients with clinical evidence of iron overload (hemochromatosis).

Elderly Patients

Clinical studies have not identified significant differences in response between elderly and younger patients. However, dose selection should be cautious, starting at the lower end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function.

Iron Dextran must be administered by a healthcare professional in a facility equipped to handle emergency allergic reactions.

• Test Dose: A 25 mg (0.5 mL) test dose is mandatory before the first therapeutic dose. The patient must be observed for at least one hour for signs of anaphylaxis.
• Intravenous Injection: Administered at a rate not exceeding 50 mg (1 mL) per minute.
• Intramuscular Injection: Must be injected into the upper outer quadrant of the buttock using the 'Z-track' technique (pulling the skin to one side before needle insertion). This prevents the medication from leaking into subcutaneous tissue, which can cause permanent skin staining.
• Storage: Store at controlled room temperature (20°C to 25°C). Do not freeze.

Since Iron Dextran is administered in a clinical setting by healthcare providers, missed doses are rare. If you miss a scheduled appointment for an injection, contact your clinic immediately to reschedule. Consistent adherence to the treatment plan is necessary to correct anemia.

Acute overdose of Iron Dextran is unlikely due to clinical administration, but chronic over-administration can lead to hemosiderosis (excessive iron accumulation in tissues). Symptoms of acute iron toxicity include abdominal pain, vomiting, and cardiovascular collapse. In cases of chronic overload, iron chelation therapy (such as deferoxamine) may be required to remove excess iron from the body.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or frequency of administration without medical guidance.

Common side effects associated with Iron Dextran administration include:

• Gastrointestinal Distress: Nausea, vomiting, and occasional abdominal pain may occur shortly after administration.
• Injection Site Reactions: For intramuscular use, pain, swelling, and brown skin discoloration at the site of injection are very common.
• Flushing: A temporary sensation of warmth or redness in the face and neck during IV infusion.
• Hypotension: A slight drop in blood pressure may occur, leading to mild lightheadedness.

• Arthralgia and Myalgia: Joint and muscle pain, which may be part of a delayed reaction appearing 1 to 3 days after treatment.
• Headache and Dizziness: General malaise or a 'heavy head' feeling.
• Fever and Chills: Shivering or a transient rise in body temperature.
• Urticaria: Mild skin rashes or itching (pruritus).
• Lymphadenopathy: Swelling of the lymph nodes.

• Seizures: Extremely rare neurological events.
• Hemolysis: Breakdown of red blood cells in certain susceptible individuals.
• Chest Pain: Non-specific chest tightness or discomfort.
• Disseminated Intravascular Coagulation (DIC): A very rare and serious blood clotting disorder.

> Warning: Stop receiving Iron Dextran and call your doctor immediately if you experience any of these symptoms during or after the injection:

• Anaphylaxis: Signs include difficulty breathing, swelling of the throat or tongue, a rapid or weak pulse, and a sudden drop in blood pressure. This is a life-threatening emergency.
• Severe Hypotension: Feeling like you might pass out or severe fainting spells.
• Convulsions: Uncontrolled muscle movements or loss of consciousness.
• Cardiac Arrest: Sudden loss of heart function, which has been reported in rare cases following iron dextran injections.
• Cyanosis: A bluish tint to the skin or lips, indicating a lack of oxygen.

The primary concern with long-term or repeated Iron Dextran use is Iron Overload (Hemosiderosis). Excessive iron can deposit in the liver, heart, and pancreas, leading to organ damage, cirrhosis, or heart failure. Regular monitoring of serum ferritin and transferrin saturation is mandatory for patients receiving long-term therapy to ensure iron levels remain within a safe therapeutic range. Additionally, permanent skin staining can occur if the Z-track technique is not properly utilized during intramuscular injections.

Iron Dextran carries a prominent FDA Black Box Warning regarding the risk of anaphylactic-type reactions. Fatal reactions have occurred following the administration of iron dextran injection. These reactions can occur even in patients who have previously tolerated the medication or who have had a negative test dose. Because of this risk, Iron Dextran should only be administered when resuscitation equipment and trained personnel are immediately available. A test dose of 25 mg must be administered prior to the first therapeutic dose, and the patient must be monitored closely for at least one hour.

Report any unusual symptoms to your healthcare provider immediately. Side effects can be reported to the FDA at 1-800-FDA-1088.

Iron Dextran is a potent medication that requires strict medical supervision. It is not a first-line treatment for iron deficiency and should only be used when oral iron is not an option. Patients with a history of multiple drug allergies or asthma may be at a higher risk for hypersensitivity reactions. It is essential to inform your doctor of your full medical history, especially any history of immune system disorders or chronic infections.

WARNING: RISK FOR ANAPHYLACTIC-TYPE REACTIONS

Anaphylactic-type reactions, including fatalities, have followed the parenteral administration of iron dextran injection. Such reactions have been reported following the first dose, the test dose, or even after multiple uneventful doses. Healthcare providers must ensure that epinephrine and other emergency resuscitative equipment are available during administration. Every patient must receive a 25 mg test dose before the full therapeutic dose is given.

• Allergic Reactions / Anaphylaxis Risk: The risk is highest in patients with significant allergies, asthma, or rheumatoid arthritis. Pre-medication with antihistamines is sometimes used, though it does not eliminate the risk of severe reactions.
• Iron Overload: Patients with conditions that cause iron accumulation, such as hemochromatosis or hemosiderosis, should never receive Iron Dextran. Over-treatment can lead to systemic toxicity.
• Cardiovascular Stress: Patients with pre-existing heart disease may be more susceptible to the hemodynamic changes (like hypotension) that can occur during infusion.
• Infection Risk: There is a theoretical concern that iron may enhance the growth of certain bacteria. Use with caution in patients with active systemic infections.

Patients receiving Iron Dextran require regular laboratory monitoring to ensure safety and efficacy:

• Hemoglobin and Hematocrit: To track the resolution of anemia.
• Serum Ferritin: To assess total body iron stores.
• Transferrin Saturation (TSAT): To ensure iron is being effectively transported and used.
• Reticulocyte Count: An early indicator of the bone marrow's response to iron therapy.
• Liver Function Tests: Periodically checked if long-term therapy is required.

Iron Dextran may cause dizziness or lightheadedness, particularly immediately following an injection or infusion. Patients should wait to see how they feel after the procedure before attempting to drive or operate heavy machinery. It is often recommended to have someone else drive you home after your first few treatments.

There are no known direct interactions between alcohol and Iron Dextran. However, chronic alcohol use can damage the liver and interfere with the body's ability to process iron. Discuss your alcohol consumption with your doctor, especially if you have underlying liver concerns.

Iron Dextran therapy is typically discontinued once the calculated iron deficit has been replaced and iron stores (ferritin) have reached a target level. There is no 'withdrawal syndrome' associated with stopping Iron Dextran, as it is not a daily maintenance medication. However, if the underlying cause of iron loss (e.g., internal bleeding) is not addressed, anemia may recur.

> Important: Discuss all your medical conditions with your healthcare provider before starting Iron Dextran.

• Oral Iron Supplements: Iron Dextran should not be used concurrently with oral iron. The administration of parenteral iron can significantly reduce the absorption of oral iron from the gastrointestinal tract. Furthermore, combining both increases the risk of iron overload. Oral iron should typically be stopped at least 24 hours before an Iron Dextran injection.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): There is evidence suggesting that patients taking ACE inhibitors may have an increased risk of systemic reactions, including anaphylactoid symptoms, when receiving IV iron dextran. The mechanism may involve the accumulation of bradykinin. Healthcare providers should monitor these patients with extra vigilance.
• Dimercaprol (BAL): This chelating agent can form toxic complexes with iron. It should not be used in patients receiving iron therapy.

• Chloramphenicol: This antibiotic may delay the response to iron therapy by interfering with the incorporation of iron into red blood cells (erythropoiesis).
• Methyldopa: Parenteral iron may interfere with the absorption and efficacy of methyldopa, though this is more common with oral iron.

Because Iron Dextran is administered by injection, food does not affect its absorption. There are no specific dietary restrictions required while receiving this medication. However, maintaining a balanced diet rich in vitamins (like Vitamin C, which aids natural iron handling) is generally encouraged for patients with anemia.

• St. John's Wort: While no direct interaction exists, St. John's Wort can affect the metabolism of many drugs; however, since iron dextran is processed by macrophages, the clinical impact is likely minimal.
• High-Dose Calcium Supplements: These do not interfere with injected iron, unlike their significant inhibitory effect on oral iron absorption.

Iron Dextran can interfere with several laboratory tests for up to 1-2 weeks after administration:

• Serum Bilirubin: May be falsely elevated due to the dark color of the iron dextran complex in the serum.
• Serum Calcium: May be falsely decreased when measured using certain laboratory methods.
• Bone Scans: Iron Dextran may cause increased uptake of technetium-99m diphosphonate in the liver or at the injection site, potentially interfering with the interpretation of bone scans.
• Blood Glucose: Some older testing methods might be affected, though modern enzymatic tests are generally stable.

For each major interaction, the management strategy usually involves either temporary discontinuation of the interacting agent or increased clinical monitoring during the period of iron administration.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Iron Dextran must NEVER be used in the following conditions:

• Known Hypersensitivity: Any patient who has previously had a severe allergic reaction or anaphylaxis to iron dextran or any of its components.
• Non-Iron Deficiency Anemia: This includes hemolytic anemia, sideroblastic anemia, or anemia of chronic disease where iron stores are already normal or high. Administering iron in these cases can lead to dangerous iron overload.
• Iron Overload: Patients with hemochromatosis or hemosiderosis must not receive this drug, as it will exacerbate tissue damage from excess iron.

Conditions requiring careful risk-benefit analysis include:

• Active Infection: Bacteria require iron to grow; therefore, parenteral iron might theoretically worsen an acute systemic infection.
• Severe Hepatic Disease: Since the liver processes and stores iron, impaired liver function may increase the risk of toxicity.
• Rheumatoid Arthritis: Patients with active RA may experience an exacerbation of joint pain and swelling following iron dextran administration.
• History of Asthma or Eczema: These patients are statistically at a higher risk for developing hypersensitivity reactions to the dextran component.

Patients who are allergic to other dextran-containing products (such as Dextran 40 or Dextran 70 used as plasma expanders) may have a cross-sensitivity to Iron Dextran. It is vital to disclose any past reactions to IV fluids or other iron products (like Iron Sucrose or Ferric Carboxymaltose) to your healthcare provider, although the dextran component is unique to this specific formulation.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Iron Dextran.

Iron Dextran is classified as FDA Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus, and there are no adequate and well-controlled studies in humans. However, the potential benefits may warrant use of the drug in pregnant women despite potential risks, especially if severe anemia poses a threat to the mother or the pregnancy. Iron deficiency anemia during pregnancy is associated with increased risks of preterm birth and low birth weight. Use during the first trimester is generally avoided unless absolutely necessary. If used, it should be administered with extreme caution due to the risk of maternal anaphylaxis, which can cause fetal distress.

Trace amounts of iron dextran are excreted in breast milk. While the amount of iron the infant receives via milk is likely negligible and not expected to cause harm, the long-term effects are not well-documented. Healthcare providers usually consider the benefits of treating the mother's anemia against the potential risks to the nursing infant. Monitoring the infant for gastrointestinal changes (like constipation) is a reasonable precaution.

Iron Dextran is approved for use in pediatric patients for the treatment of iron deficiency anemia. However, it is generally not recommended for infants under 4 months of age due to lack of safety data in this specific age group. Dosing in children must be meticulously calculated based on weight and hemoglobin levels to avoid accidental iron poisoning. Growth and development should be monitored as part of the overall management of anemia.

Elderly patients may be at a higher risk for adverse cardiovascular effects, such as hypotension, during Iron Dextran infusion. Because older adults are more likely to have multiple comorbidities (like heart or kidney disease) and take multiple medications (polypharmacy), the risk of drug interactions (e.g., with ACE inhibitors) is higher. Renal clearance of the dextran component may also be slower in the elderly. Healthcare providers typically start with smaller, more frequent doses rather than a single large infusion.

In patients with chronic kidney disease (CKD), Iron Dextran is often used to manage anemia, particularly for those on hemodialysis. While the iron itself is not cleared by the kidneys, the dextran polysaccharide component is. No specific dose adjustment is required based on GFR, but iron status must be monitored very closely to prevent overload, as these patients often receive multiple blood transfusions and other iron-stimulating therapies.

Iron Dextran should be used with significant caution in patients with hepatic impairment (Child-Pugh Class B or C). The liver is the primary storage organ for iron (as ferritin). In patients with liver damage, the risk of iron-induced hepatotoxicity is increased. Regular monitoring of liver enzymes and iron markers is essential.

> Important: Special populations require individualized medical assessment and close clinical monitoring.

Iron Dextran is a complex of ferric hydroxide with dextran. Following administration, the complex is taken up by the cells of the reticuloendothelial system (RES), particularly macrophages. Within these cells, the iron is dissociated from the dextran shell. The released ferric iron ($Fe^{3+}$) then binds to endogenous transferrin, the primary iron transport protein in human plasma. This iron-transferrin complex is then delivered to the erythroid precursor cells in the bone marrow, where it is internalized and the iron is incorporated into the protoporphyrin ring to form heme, and subsequently, hemoglobin.

The primary pharmacodynamic effect of Iron Dextran is the increase in hemoglobin production and the replenishment of depleted iron stores. The onset of action is not immediate; while serum iron levels rise quickly, an increase in the reticulocyte count (new red blood cells) is typically seen within 3 to 7 days. A significant rise in hemoglobin levels usually takes 2 to 4 weeks of therapy. The duration of effect depends on the total dose administered and the patient's ongoing iron loss.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (IV); ~60-90% (IM) |

| Protein Binding | Very high (as transferrin-bound iron) |

| Half-life | 5-20 hours (dose-dependent) |

| Tmax | Immediate (IV); 24-72 hours (IM) |

| Metabolism | RES macrophage dissociation |

| Excretion | Minimal (Renal <1%, Fecal <1%) |

Iron Dextran is a dark brown, slightly viscous liquid. Its molecular formula is approximately $[FeO(OH)]_n[C_6H_{10}O_5]_m$. It has a high molecular weight of approximately 165,000 Daltons. The complex is highly soluble in water and stable at a physiological pH of 5.2 to 6.5. The dextran component is a polymer of glucose. Unlike simple iron salts, the dextran complex prevents the rapid release of free iron into the plasma, which would otherwise be toxic.

Iron Dextran is classified as an Iron Replacement Product or Parenteral Hematinic. It is part of a group of medications that includes Iron Sucrose (Venofer), Ferric Gluconate (Ferrlecit), and Ferric Carboxymaltose (Injectafer). Among these, Iron Dextran is unique due to its high molecular weight and the mandatory requirement for a test dose due to the dextran-associated anaphylaxis risk.